TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Safety and efficacy of teclistamab in patients with RRMM exposed to anti-BCMA: MajesTEC-1 Cohort C

By Jennifer Reilly

Share:

Aug 30, 2024

Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory multiple myeloma.



Teclistamab, a B-cell maturation antigen (BCMA)-directed bispecific antibody therapy, was investigated and granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (RRMM) as a result of the pivotal MajesTEC-1 (NCT04557098) trial. Results from Cohort C of MajesTEC-1 trial on safety and efficacy of teclistamab in patients with prior exposure to anti-BCMA therapies were published in Blood by Touzeau, et al.1


Key learnings:

An overall response rate (ORR) of 52.5% was observed, with 47.5% of patients experiencing a very good partial response or better (≥VGPR) and 30% a complete response or better (≥CR).

  • Response rates were similar among patients treated with prior BCMA-targeted antibody–drug conjugates vs chimeric antigen receptor (ORR, 55.2% vs 53.3%; ≥VGPR, 48.3% vs 46.7%; ≥CR, 27.6% vs 26.7%, respectively).

The median progression-free survival and overall survival were 4.5 months and 15.5 months, respectively.

The most common any grade treatment-emergent adverse events (TEAEs) included neutropenia, infections, and cytokine release syndrome. 

  • Cytopenias and infections were the most frequent severe (Grade ≥3) TEAEs. 
  • 32.5% of patients experienced Grade 3–4 infections, while 10% experienced Grade 5 infections.

The safety profile of teclistamab was largely comparable in patients with and without prior exposure to anti-BCMA therapy.

The findings from the study demonstrate the clinical benefit of teclistamab as a therapeutic option for patients with RRMM previously treated with BCMA-targeted therapies.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content